Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.1.75NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.51NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.106NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
D.2NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.593NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.438.1NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.1.513NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.338NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.284NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.9.2NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.498NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.184NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.187NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
D.3NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
AE.2NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.110.1NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.1.342NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.500NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.511NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.428.1NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.506NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.482NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.1.335NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.36.36NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.499.1NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.38NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.1.116NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.134NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.1.393NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.1.381NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
C.32NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
AE.8NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.1.516NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.1.526NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.279NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.338NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23778.3US
B.1.371NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23778.3US
B.1.333NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23778.3US
HN.6SWuhanCoV-spk1TGTGGTTCATAAAAATTCCTTTGTG25322490024876R-23698.9Japan
XAY.3ORF1abNIID WH-1 F501R913CTTTACCAGCACGTGCTAGAAGG2352.17896874R-23621.9Japan
A.6ORF1abNIID WH-1 F501R913CTTTACCAGCACGTGCTAGAAGG2352.17896874R-23621.9Japan
AY.109 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23619.5US
KN.1.1NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23604.3China
B.1.256NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23594.8US
B.1.256EHuang-EGCAGCAGTACGCACACAATC20552637626357R-23540.5China
B.26EHuang-EGCAGCAGTACGCACACAATC20552637626357R-23540.5China
B.1.177.77EHuang-EGCAGCAGTACGCACACAATC20552637626357R-23540.5China
B.34EHuang-EGCAGCAGTACGCACACAATC20552637626357R-23540.5China
B.1.248EHuang-EGCAGCAGTACGCACACAATC20552637626357R-23540.5China
B.32EHuang-EGCAGCAGTACGCACACAATC20552637626357R-23540.5China
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used